Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios

Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI‐sensitive and multikinase inhibitors, lenvatinib and sorafenib, when the disease becomes RAI‐refractory. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Zafón, Carles, Castelo, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537053/
https://www.ncbi.nlm.nih.gov/pubmed/36202604
http://dx.doi.org/10.1002/cam4.5154
_version_ 1784803112705327104
author Zafón, Carles
Castelo, Beatriz
author_facet Zafón, Carles
Castelo, Beatriz
author_sort Zafón, Carles
collection PubMed
description Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI‐sensitive and multikinase inhibitors, lenvatinib and sorafenib, when the disease becomes RAI‐refractory. The objective of this publication is to review the current knowledge on the use of targeted therapy and the specific practical considerations concerning lenvatinib in the treatment of patients with differentiated thyroid cancer under special circumstances.[Image: see text]
format Online
Article
Text
id pubmed-9537053
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95370532022-10-12 Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios Zafón, Carles Castelo, Beatriz Cancer Med Editorial Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI‐sensitive and multikinase inhibitors, lenvatinib and sorafenib, when the disease becomes RAI‐refractory. The objective of this publication is to review the current knowledge on the use of targeted therapy and the specific practical considerations concerning lenvatinib in the treatment of patients with differentiated thyroid cancer under special circumstances.[Image: see text] John Wiley and Sons Inc. 2022-10-06 /pmc/articles/PMC9537053/ /pubmed/36202604 http://dx.doi.org/10.1002/cam4.5154 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Zafón, Carles
Castelo, Beatriz
Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
title Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
title_full Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
title_fullStr Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
title_full_unstemmed Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
title_short Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
title_sort use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537053/
https://www.ncbi.nlm.nih.gov/pubmed/36202604
http://dx.doi.org/10.1002/cam4.5154
work_keys_str_mv AT zafoncarles useofmultikinaseinhibitorslenvatinibinsingularthyroidcancerscenarios
AT castelobeatriz useofmultikinaseinhibitorslenvatinibinsingularthyroidcancerscenarios

Ejemplares similares